Brasília – A study led by Brazilian researchers identified mechanisms that help certain types of breast cancer escape targeted therapies, including treatments directed at the HER2 protein. According to the findings, some tumors modify the structure of HER2 or rely on alternative pathways, making it difficult for therapies to bind effectively or block tumor growth. The research helps explain why many patients classified as HER2-positive or HER2-low do not respond adequately to available drugs.

The investigators found that tumor cells may express different forms of the HER2 protein or reduce its presence on the cell surface, leading to partial or complete resistance to treatment. The study also highlights the need for more precise molecular characterization of tumors and for the development of therapies capable of addressing biomarker variability. Researchers note that the discoveries could influence future diagnostic criteria and therapeutic strategies.

Source: Folha de S.Paulo